Insulet (PODD) Expected to Announce Earnings on Wednesday

Insulet (NASDAQ:PODD) is expected to be issuing its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect the company to announce earnings of $1.48 per share and revenue of $768.3080 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 18, 2026 at 8:00 AM ET.

Insulet Price Performance

PODD stock opened at $252.41 on Wednesday. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.68. Insulet has a 12-month low of $230.05 and a 12-month high of $354.88. The stock has a 50-day moving average price of $281.06 and a two-hundred day moving average price of $307.47. The company has a market cap of $17.76 billion, a PE ratio of 73.16, a price-to-earnings-growth ratio of 1.39 and a beta of 1.41.

Analysts Set New Price Targets

PODD has been the topic of several analyst reports. Zacks Research downgraded Insulet from a “strong-buy” rating to a “hold” rating in a report on Monday, January 5th. Stifel Nicolaus decreased their price target on shares of Insulet from $370.00 to $350.00 and set a “buy” rating for the company in a research report on Wednesday, February 4th. Wells Fargo & Company increased their target price on Insulet from $350.00 to $360.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Canaccord Genuity Group increased their target price on Insulet from $432.00 to $450.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Finally, Jefferies Financial Group lifted their price objective on shares of Insulet from $375.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Twenty equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $374.10.

Hedge Funds Weigh In On Insulet

Several hedge funds have recently bought and sold shares of the business. Glenmede Investment Management LP grew its stake in Insulet by 1.6% in the 3rd quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after buying an additional 35 shares during the last quarter. Curi Capital LLC grew its holdings in shares of Insulet by 0.8% in the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after purchasing an additional 36 shares during the last quarter. Camarda Financial Advisors LLC grew its position in Insulet by 0.5% during the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock worth $2,304,000 after acquiring an additional 40 shares during the last quarter. Hilltop Holdings Inc. raised its holdings in shares of Insulet by 1.6% in the third quarter. Hilltop Holdings Inc. now owns 2,896 shares of the medical instruments supplier’s stock valued at $894,000 after buying an additional 47 shares during the last quarter. Finally, NewEdge Advisors LLC raised its position in Insulet by 44.8% in the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock worth $54,000 after purchasing an additional 64 shares during the last quarter.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.